Journal article
Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults with transplant‐ineligible multiple myeloma: A network meta‐analysis
- Abstract:
-
Background:
Multiple myeloma is a bone marrow‐based hematological malignancy accounting for approximately two per cent of cancers. First‐line treatment for transplant‐ineligible individuals consists of multiple drug combinations of bortezomib (V), lenalidomide (R), or thalidomide (T). However, access to these medicines is restricted in many countries worldwide.Objectives:
Expand abstract
To assess and compare the effectiveness and safety of multiple drug ...
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 3.6MB, Terms of use)
-
- Publisher copy:
- 10.1002/14651858.cd013487
Authors
- Publisher:
- Cochrane Collaboration
- Journal:
- Cochrane Database of Systematic Reviews More from this journal
- Volume:
- 2019
- Issue:
- 11
- Pages:
- 1-150
- Publication date:
- 2019-11-25
- Acceptance date:
- 2019-11-21
- DOI:
- EISSN:
-
1469-493X
- Pmid:
-
31765002
- Language:
-
English
- Keywords:
- Pubs id:
-
pubs:1075320
- UUID:
-
uuid:1685e6dd-e67d-43c0-ae8c-655029c8f432
- Local pid:
-
pubs:1075320
- Source identifiers:
-
1075320
- Deposit date:
-
2019-12-02
Terms of use
- Copyright holder:
- Cochrane Collaboration
- Copyright date:
- 2019
- Rights statement:
- Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
- Notes:
- This is the publisher's version of the article. The final version is available online from the Cochrane Collaboration at: https://doi.org/10.1002/14651858.CD013487
If you are the owner of this record, you can report an update to it here: Report update to this record